更新于：2024-11-21

Ethynodiol diacetate/mestranol

双醋炔诺醇/美雌醇

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名

OVULEN-21、OVULEN-28、Ovulen

靶点

作用机制

PR激动剂(孕激素受体激动剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

Viatris Holdings LLC

在研机构-

非在研机构

Viatris Holdings LLC

最高研发阶段撤市

首次获批日期

美国 (1966-03-23)

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C21H26O2

InChIKeyIMSSROKUHAOUJS-MJCUULBUSA-N

CAS号72-33-3

查看全部结构式(2)

关联

100 项与双醋炔诺醇/美雌醇相关的临床结果

登录后查看更多信息

100 项与双醋炔诺醇/美雌醇相关的转化医学

登录后查看更多信息

100 项与双醋炔诺醇/美雌醇相关的专利（医药）

登录后查看更多信息

项与双醋炔诺醇/美雌醇相关的文献（医药）

1984-07-01·Journal of the Royal Society of Medicine3区 · 医学

Exogenous Hormones in the Aetiology of Cancer in Women

3区 · 医学

Review

作者: Vessey, M P

Both animal experimental work and epidemiological clinical and laboratory research on the effects of endogenous hormones in the human have made it clear that some influence of administered female sex hormones on the risk of certain cancers would be anticipated and this has turned out to be the case. This review focuses on the administration of hormones during pregnancy around the time of the menopause and to prevent pregnancy. In the daughters who were exposed in utero to stilbestrol during the 1950s and 1960s the most important effect is the development of clear cell adenocarcinoma of the vagina or cervix. Few cases of this disease have been reported before puberty but the cumulative risk thereafter up to the age of 24 years is estimated to be between 1.4 and 4/10000 exposed. Much less attention has been paid to the mothers who actually took the stilbestrol than to their daughters but the published data fail to provide any convincing evidence of an increased risk of either breast or reporductive cancer among them. Regarding the administration of hormones around the time of menopause it is well established that unopposed estrogen therapy in menopausal women can cause endometrial cancer. This has been demonstrated in a large number of case control studies reported since 1975. Most of these studies were conducted in the US and most concern the drup Premarin (conjugated equine estrogens). Some cohort studies also have been reported and they largely support the results of the case control studies. There is now little doubt that combined oral contraceptives (OCs) protect against both epithelial ovarian cancer and endometrial cancer. Preliminary findings in the major cohort studies concerned with the longterm effects of OC use also are encouraging. A series of large case control studies conducted during the 1970s showed clearly that there is no general association between oral contraceptive use and breast cancer risk but these large studies included few women with appreciable OC use at an early age and accordingly the publication by Pike et al. in 1981 caused much concern. Pikes study involved 163 women in Los Angeles County in whom breast cancer has been diagnosed at age 32 or less together with a like number of neighborhood controls. Vessey et al. (1982) and the Centers for Disease control subsequently published results which did not support the California findings. Preliminary results from a new case control study conducted in Oxford and in London since 1980 suggest an increased risk of breast cancer in young women who have prolonged OC use before 1st pregnancy. The situation is very confusing and it may be some time before there is a conclusive answer. In a large cohort study conducted in Los Angeles rates of progression from cervical dysplasia to carcinoma in situ were much higher in women using Ovulen than in women using IUDs.

1983-12-01·The Lancet1区 · 医学

PROGESTAGEN "POTENCY" AND BREAST CANCER

1区 · 医学

Letter

作者: Swyer, G.I.M.

The validity of the table of oral contraceptive (OC) formulations ranked according to their progestagen potency by Pike et al. and of the table derived from this and published by the Committee on Safety of Medicines is refuted. It is noted that the delay of menses test used by Pike relates only to endometrial hemostatic efficacy and provides no evidence for ranking synthetic progestagens and by any other property. Moreover even if this criterion is used only those formulations containing 50 mcg ethinyl estradiol and the progestagens norethisterone norethisterone acetate ethynodiol diacetate norgestrel and levonorgestrel can be compared. Acceptable data do not exist for the rest of the formulations. There are only 12 OC formulations (Eugynon 50 Ovran Neogynon Neogynon ED Ovulen 50 Anovlar 21 WY 125 D/50 Gynovlar 21 Norlestrin Minovlar Minovlar ED and Orlest 21) for which potency ratios can theoretically be deduced from the delay of menses data for mixtures containing 50 mcg ethinyl estradiol.

1983-12-01·The American Journal of the Medical Sciences4区 · 医学

Case Report: Familial Central Diabetes Insipidus: Vasopressin and Nicotine Stimulated Neurophysin Deficiency with Subnormal Oxytocin and Estrogen Stimulated Neurophysin

4区 · 医学

Article

作者: Piers R. Blackett ; Dale H. Altmiller ; Alan G. Robinson ; Said M. Seif

Five members of a family with dominantly inherited diabetes insipidus were diagnosed and treated with deamino-d-arginine vasopressin (DDAVP), a vasopressin analogue given intranasally. All subjects demonstrated subnormal levels of arginine vasopressin (AVP) by radioimmunoassay in response to cigarette smoke inhalation, a standardized nicotine stimulation test. Levels of oxytocin (OT) were found to be normal and unstimulated after cigarette inhalation in two subjects, but when two affected male siblings ingested Ovulen, OT and ESN were stimulated to subnormal levels. After twelve months of DDAVP treatment, the low AVP response to nicotine was preserved whereas the carrier protein, nicotine stimulated neurophysin (NSN) remained undetectable.

100 项与双醋炔诺醇/美雌醇相关的药物交易

登录后查看更多信息